YDS Pharmatech

YDS Pharmatech provides an advanced structure-based de novo drug design service leveraging proprietary evolutionary AI and biophysics simulations. Their MERES/MOPFI platforms enable rapid identification and optimization of novel drug candidates with minimal input data, bypassing the need for large training datasets typical in conventional AI approaches. The company has demonstrated success in accelerating partner programs—including a >100-fold increase in binding affinity for a PROTAC candidate against a challenging target, discovery of the world’s first alphavirus inhibitor, and generation of new IP for allosteric kinase inhibitors.